

Patrick Ellsworth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3579870/publications.pdf>

Version: 2024-02-01

9
papers

99
citations

1684188
5
h-index

1720034
7
g-index

9
all docs

9
docs citations

9
times ranked

145
citing authors

#	ARTICLE	IF	CITATIONS
1	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. <i>Blood</i> , 2019, 133, 2529-2541.	1.4	51
2	Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort. <i>Blood Advances</i> , 2020, 4, 6240-6249.	5.2	15
3	Pregnancy in sickle cell trait: what we do and don't know. <i>British Journal of Haematology</i> , 2020, 190, 328-335.	2.5	12
4	High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2329-2340.	3.8	7
5	Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 219-225.	2.5	7
6	Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A. <i>Haemophilia</i> , 2021, 27, e585-e588.	2.1	6
7	Rituximab Monotherapy Is Effective for Inhibitor Eradication with Concomitant Porcine Factor VIII Followed By Emicizumab for Bleed Control in Acquired Hemophilia a. <i>Blood</i> , 2021, 138, 348-348.	1.4	1
8	Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy. <i>Haemophilia</i> , 2021, 27, e147-e150.	2.1	0
9	Emicizumab Promotes Factor Xa Generation on Activated Endothelium in a Blood Cell-Independent Manner. <i>Blood</i> , 2021, 138, 3182-3182.	1.4	0